WilmerHale Represents Verve Therapeutics in $94M Series B Financing

Download IconDownload Print IconPrint

WilmerHale Represents Verve Therapeutics in $94M Series B Financing

Client News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

On January 19, 2021, Verve Therapeutics, a biotech company pioneering gene editing medicines to treat cardiovascular disease, announced the successful completion of a $94 million Series B financing, led by Wellington Management Company and co-led by Casdin Capital, existing investors. New investors in the funding included Redmile Group, Janus Henderson Investors, Cormorant Asset Management, Rock Springs Capital, Novo Holdings A/S, Logos Capital, Surveyor Capital (a Citadel company), RA Capital Management, and a US-based, healthcare-focused fund, alongside additional existing investors GV and Biomatics.

Proceeds from the financing will be used to advance the company’s pipeline of gene editing medicines, led by VERVE-101, and further extend its scientific and technical leadership.

The WilmerHale team representing Verve includes Lia Der Marderosian, Timothy Kulis and Meghan Muncey.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel